BioBridge Global con
BioBridge Global continues history of innovation with umbilical cord collection and processing under cGMP standards for further manufacture
18 nov. 2021 09h00 HE | BioBridge Global
San Antonio, Texas, Nov. 18, 2021 (GLOBE NEWSWIRE) -- BioBridge Global is committed to supporting advanced therapies through the development and delivery of services from source material collection,...
TIP_link_300x300.jpg
Inspection Machines Market Size ($1,172.99Mn by 2028) Lead by Vision Inspection Systems (5.3% CAGR) Impact of Coronavirus Outbreak and Global Analysis & Forecast by TheInsightPartners.com
03 nov. 2021 10h25 HE | The Insight Partners
New York, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Inspection Machine Market: Key InsightsAccording to our new research study on Inspection Machines Market Size, Share, Revenue, Forecast to 2028 - Covid-19...
22157.jpg
Global Flexible Manufacturing Systems in the Pharmaceutical Industry Market (2021 to 2026) - Rising Opportunities with Industry 4.0 and Pharma 4.0
26 oct. 2021 07h23 HE | Research and Markets
Dublin, Oct. 26, 2021 (GLOBE NEWSWIRE) -- The "Global Market for Flexible Manufacturing Systems in the Pharmaceutical Industry" report has been added to ResearchAndMarkets.com's offering. This...
image
Josh Wilhelm Joins PetVivo Holdings, Inc. as the Director of Manufacturing
08 sept. 2021 08h00 HE | PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, Sept. 08, 2021 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV) (the "Company") an emerging biomedical device company focused on the commercialization of innovative...
87520785_101152591495741_6497961433500745728_o.jpg
Psychedelic Joint Venture Between Mycotopia Therapies and Natural MedTech Brings Research and Drug Development to Test Active Ingredient In Psychedelics
22 mars 2021 07h00 HE | 20/20 Global, Inc.
MIAMI, March 22, 2021 (GLOBE NEWSWIRE) -- 20/20 Global, Inc. dba Mycotopia Therapies, (OTC Pink: TWGL) (the “Company”), a company focused on psychedelic therapies, announced today it has formed...
Cytovance_HepaLink_Digtial_032017.jpg
Cytovance Biologics now offering Licensing for Plasmid DNA Manufacturing
08 mars 2021 03h00 HE | Cytovance Biologics
OKLAHOMA CITY, March 08, 2021 (GLOBE NEWSWIRE) -- Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO) of mammalian, microbial biologics and...
Cytovance_HepaLink_Digtial_032017.jpg
Cytovance Biologics offers Nature Technology Corporation’s proprietary HyperGRO™ manufacturing platform for plasmid DNA CGMP manufacturing
30 nov. 2020 03h00 HE | Cytovance Biologics
OKLAHOMA CITY, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO) of mammalian, microbial biologics and...
provectus_logo.jpg
Provectus Biopharmaceuticals Highlights Stage IV M1c Patient Outcome from Combination Therapy Trial of PV-10® and KEYTRUDA® for Checkpoint-Naïve Advanced Cutaneous Melanoma at ESMO Virtual Congress 2020
21 sept. 2020 12h45 HE | Provectus Biopharmaceuticals Inc.
Near-resolution of tumor burden, including extensive visceral hepatic diseaseExpanded data set of trial subject provided KNOXVILLE, TN, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT)...
22157.jpg
Global CDMO Industry Insights Report 2019-2025: Market Size Breakdown by Type of Service, Type of Molecule, End Use and Region
02 sept. 2020 05h19 HE | Research and Markets
Dublin, Sept. 02, 2020 (GLOBE NEWSWIRE) -- The "Global Market Opportunities and Competitive Landscape for CDMO" report has been added to ResearchAndMarkets.com's offering. This report provides an...
provectus_logo.jpg
Provectus Biopharmaceuticals Expands Sponsored Research Collaboration with University of Calgary (Canada) to Investigate Oral Administration of Rose Bengal Disodium for Cancer Treatment
13 août 2020 08h00 HE | Provectus Biopharmaceuticals Inc.
University of Calgary researchers have successfully demonstrated initial, in vivo proof-of-concept, oral rose bengal disodium treatment for blood cancerResearchers will now investigate oral treatment...